Last Updated: 13 Nov 2024
Executive Summary
Cyclacel Pharmaceuticals Inc. (CYCC) is a clinical-stage biopharmaceutical company developing drugs for cancer and other proliferative diseases. The company's market capitalization is $958,330, with 2,151,100 shares outstanding. The latest stock price is $0.41.
Company Overview
Cyclacel Pharmaceuticals was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. The company's lead drug candidate, seliciclib, is a cyclin-dependent kinase (CDK) inhibitor that is being evaluated in clinical trials for the treatment of various types of cancer.
Fundamental Analysis
Cyclacel Pharmaceuticals reported a net loss of $20,185,000 for the fiscal year ended December 2023. The company's revenue for the year was $80,000. Cyclacel Pharmaceuticals has a negative EPS of -$14.09 and a book value of $0.553. The company's profit margin is 0%, and its operating margin is -911%.
Technical Analysis
Cyclacel Pharmaceuticals' stock price has been trending down in recent months. The stock's 52-week high is $6, and its 52-week low is $0.375. The stock's 50-day moving average is $0.886, and its 200-day moving average is $1.702.
Short Term Outlook
Cyclacel Pharmaceuticals' stock price is likely to continue to trend down in the short term. The company's fundamentals are weak, and its technical indicators are bearish.
Long Term Outlook
Cyclacel Pharmaceuticals' stock price could recover in the long term if the company's clinical trials are successful. However, the company's long-term outlook is uncertain.
Analyst Recommendations
One analyst has a Strong Buy rating on Cyclacel Pharmaceuticals, and one analyst has a Buy rating. The average analyst target price is $6.
